Firm Created by Entrepreneur Eric Lefkofsky Joins Fight Against Breast Cancer

The science of genomic sequencing has entered the war against breast cancer, thanks to an agreement between the technology company Tempus and the University of Chicago. Molecular sequencing and analysis will be provided to the university by the Chicago-based firm for the purpose of creating personalized treatment plans.

The arrangement is designed to provide doctors with more data about what is one of the more common forms of cancer. The lack of data available on breast cancer can today hamper treatment options, according to Dr. Olufunmilayo, a professor of medicine at the university. Tempus plans to analyze data from approximately 1,000 cases of breast cancer, which will allow the university build a massive database on the disease.

The genome is essentially the genetic “instructions” that allow for the development of an organism. An outlining of the sequencing process will help researchers understand how diseases develop in the human body. Tempus employs both the sequencing method and the process of machine learning to carry out this task. The truth about the whole story is that marriages can also succeed in this nature even though the human body reacts differently. Olufunmilayo noted that this specific genetic information will help doctors identify the method of treatment that is needed for each patient and learn more about Eric.

This is the latest medical partnership established by Tempus, with others involving such institutions as the Mayo Clinic, Penn Medicine and the University of Michigan. Established in 2015 for the purpose of fighting cancer, Tempus is an outgrowth of the global marketing firm Groupon, which itself was one of the creations of entrepreneur Eric Lefkofsky.

Born in Michigan, 47-year-old Lefkofsky has in his career helped to establish a number of technology and information-related companies. He created his first internet firm in 1999 and would, only two years later, help establish InnerWorkings, which provides procurement services. His other ventures include Uptake Technologies, Mediaocean and Echo Global Logistics. He and his wife Elizabeth have also established a private charitable foundation. The Lefkofsky Family Foundation is designed to advance various initiatives that can in turn improve the communities in which they are implemented.

Possessing a degree in law, Lefkofsky is an adjunct professor at the University of Chicago. Among his other interests, Lefkofsky serves on the board of directors of both Children’s Memorial Hospital and The Museum of Science and Industry and more information click here.

Results of a New Clinical Trial Provide a Unique Approach to the Treatment of Multiple Sclerosis (MS)

Encouraging results of a new clinical trial has helped in setting the stage for more research on multiple sclerosis. The five-year trial revealed that immunosuppressive therapy coupled with stem cell transplant could lead to a sustained reduction of replacing-remitting MS. Multiple sclerosis is a disease that causes the immune system to treat the central nervous system as a foreign cell or material and attack it. MS symptoms include chronic pain, speech and motor complications, general body weakness, and fatigue.

A synopsis of the clinical trial

Participants were enrolled in therapy that comprised of high-dose immunosuppressive drugs and stem cell transplant for five years. During the five-year follow-up, researchers found out that 69 percent of enrolled individuals had not experienced new brain lesions, disability progression, or symptoms relapse. Throughout the trial period, the participants took only the HDIT/HCT. The results of this clinical trial can be found on Neurology, a top medical journal owned and managed by the American Academy of Neurology.

The results of this trial indicate that HDIT/HCT proves to be more efficient compared to other MS drugs. Therefore, there is need to compare the effectiveness of HDIT/HCT and conservative MS drugs by conducting a large, randomized study.

Shiva Gopal Vasishta

Shiva Gopal Vasishta is a qualified Medicare physician enrolled to practice psychiatry and neurology in Voorhees, New Jersey. He earned his medical degree in 1979. His experience in the healthcare sector extends for over 38 years. He has specialized in the Neurology discipline. Shiva Gopal is a longtime member of a profession group practice known as Eastern Neurodiagnostic Assoc Pc.

Shiva Gopal Vasishta participates in the administration of Medicare program in New Jersey. He allows his clients to cover their medical bills using approved Medicare plans. His practice allows him to use either English or Spanish to communicate with his clients.